Oesophageal cancer (OC) is one of the most fatal malignancies in the world, and chemoresistance restricts the therapeutic outcome of OC. Long noncoding RNA (lncRNA) was reported to play roles in multiple cancer types. Yet, the function of lncRNA in chemoresistance of OC has not been The prognosis of OC is relatively poor, even in the early stage of surgery. After resection of the lesion, the patient's 5-year survival rate is still less than 20%. 3, 4 The overall 1-, 3-, and 5-year survival rates for OC were 76.6%, 27.3%, and 12.3%. 5 The median survival for OC after recurrence was 8 months, and the 1-, 3-, and 5-year postrecurrence survival rates were 45.9%, 10.6%, and 6.4%, respectively. 
| INTRODUCTION
Oesophageal cancer (OC) is a common human gastrointestinal cancer; the occurrence rate is the eighth in the world. Oesophageal cancer mortality ranked the sixth in all cancer types. 1, 2 The incidence of OC has obvious geographical distribution characteristics, with high incidence areas including South Africa, East Asia, and East Africa, 2 and high incidence of countries or regions including China, Japan, South Africa, and the northeast of the United States. Oesophageal cancer refers to the formation of malignant lesions from oesophageal squamous epithelium or glandular epithelial hyperplasia, and the development to general epithelial dysplasia, in situ carcinoma, invasion cancer, and other stages.
The prognosis of OC is relatively poor, even in the early stage of surgery. After resection of the lesion, the patient's 5-year survival rate is still less than 20%. 3, 4 The overall 1-, 3-, and 5-year survival rates for OC were 76.6%, 27.3%, and 12.3%. 5 The median survival for OC after recurrence was 8 months, and the 1-, 3-, and 5-year postrecurrence survival rates were 45.9%, 10.6%, and 6.4%, respectively. 5 The 55.8% of patients recurred within 1 year, 81.1% within 2 years, and 88.9% within 3 years after esophagectomy. 5 Chemoresistance is a main reason for the recurrence.
Long noncoding RNA (lncRNA) is an open reading frame of endogenous cellular RNA; the length is more than 200 nucleotides. 6 The mammalian genome contains a large number of lncRNAs. 6 Long noncoding RNAs constitute a very complex RNA molecule group that plays a wide range of molecular and cellular functions. 6 Researchers found that lncRNA regulated gene expression in the form of RNA at levels of epigenetic level, transcription level, and posttranscriptional level. 7 Long noncoding RNA is closely related to the development and progression of human diseases, such as lung cancer, bladder cancer, breast cancer, gastrointestinal cancer, and prostate cancer. [8] [9] [10] [11] [12] [13] [14] Long noncoding RNA PCAT-1 plays important roles in a variety of cancer types. [14] [15] [16] [17] However, although PCAT-1 was mentioned in connection with OC, 18 the roles of PCAT-1 in OC cells growth and proliferation, especially chemotherapy resistance, has not been reported.
This study will provide new and important molecular targets for the diagnosis and treatment of OC. 
| MATERIALS AND METHODS

| Patient samples
| MTT assay
Cells were plated in 96-well plates at 10 000 per well for 24 hours.
Next, 10 μL of MTT at concentration of 5 mg/mL was added to each well and incubated at 37°C in the dark for 4 hours. Then 100 μL dimethyl sulfoxide was added into each well and cultured in the dark for 2 hours. Finally, the reduction of MTT was quantified by measuring the absorbance at 570 nm by microplate reader.
| Colony formation assay
Colony formation assay was conducted based on the protocol in the reference in vitro with slight modifications. 19 Briefly, cells with PCAT-1 silencing or cisplatin treatment and the corresponding control cells were trypsinized, counted, and plated to 6-well plates with 100 cells/well. Ten days later, cell medium was removed, and cell colonies were fixed and stained with a mixture of 6.0% glutaraldehyde and 0.5% crystal violet, and the number of colonies was counted.
| Silencing of PCAT-1
Cells were plated in 6-well plates to reach 60% confluence on the next day, and then cells were transfected with 100 nM PCAT-1 small interfering RNA (siRNA) oligos or nontargeting controls with
Oligofectamine in OptiMEM media. PCAT-1 knockdown siRNA sequences were as follows: siRNA 1 UUAAAGAGAUCCACAGUUA UU; siRNA 2 GCAGAAACACCAAUGGAUAUU; siRNA 3 AUACAU AAGACCAU-GGAAAU; and siRNA 4 GAACCUAACUGGACUUUAA UU. 20 Seventy-two-hour posttransfection, cells were harvested for real-time PCR analysis, MTT assay, or colony formation assay.
| Annexin-V/propidium iodide double-staining assay
The 
| Xenograft mouse model
The experiments involving mice were performed according to the pro- Tumour size was measured at the indicated days post inoculation by using a calliper. Twenty-four days after injection, mice were sacrificed and xenograft tumour weight was measured.
| Statistical analysis
All data represented are the mean ± standard deviation from at least 3 independent experiments. One or 2-way ANOVA analysis was utilized to analyse the significance of differences between 2 groups. P < .05 was considered significant. , and Eca109) were tested by qRT-PCR and normalized as the ratio to the HOEC group. **P < .01 shown ( Figures 5C and 5D) . Consistently, the results demonstrated that the tumours from shPCAT-1 cells were significantly smaller than tumours from shNC cells ( Figures 5C and 5D ). This nude mice tumour formation test further confirmed the important role of PCAT-1 in the promotion of OC.
| DISCUSSION
In this study, the expression of PCAT-1 in oesophageal carcinoma was significantly higher than that in normal specimen. Because recurrence is often associated with chemotherapy resistance, it also suggests that PCAT-1 is associated with chemotherapy resistance. significantly. 21 In addition, the expression of HOTAIR in oesophageal squamous cell carcinoma was significantly higher than that in adjacent tissues, and it was significantly correlated with the metastasis, high stage, and survival rate of oesophageal carcinoma. After the HOTAIR was knocked-out, the cell invasion and migration ability decreased and the apoptotic capacity increased.
22
A novel lncRNA, PCAT-1 plays important roles in a variety of cancer. 13, 15, 20, [23] [24] [25] [26] [27] For example, PCAT-1 is involved in cell apoptosis and proliferation of prostate cancer. In addition, PCAT-1 could play an oncogenic role in gastric cancer progression. PCAT-1 was increased in gastric cancer tissues and cell lines. Overexpression of PCAT-1 was correlated with poor overall survival in gastric cancer patients. 15 It was also reported that the prostate cancer risk SNP rs7463708 promotes transformation via up-regulation of PCAT-1 lncRNA. 13 Consistently, in this study, we found that overexpression of PCAT-1 promoted OC cell proliferation and growth and PCAT-1 knock-down inhibited OC cell proliferation and growth, demonstrating that PCAT-1 seems function as an oncogene of OC.
PCAT-1 was mentioned in connection with OC. 18 It was found that PCAT-1 were involved in somatic copy-number alterations or structural variants, and it was significantly associated with poorer survival on a survival analysis based on the expression profiles of 321 individuals with OC. 18 However, the role of PCAT-1 in OC expression and growth and proliferation has not been studied previously.
Importantly, the genetic mechanisms underlying the chemoresistance of OC are not well understood. This study demonstrated that PCAT-1 overexpression could promote the proliferation and growth of OC cells. PCAT-1 knock down could inhibit the proliferation and growth of OC cells. Importantly, PCAT-1 knock down enhanced the chemosensitivity of OC on cisplatin by inhibiting cancer cell growth and proliferation and inducing cancer cell apoptosis.
Results from in vivo OC xenograft model showed that knock down of PCAT-1 significantly inhibited tumour growth and development.
These findings provide novel and important molecular targets for the diagnosis and treatment of OC.
| CONCLUSIONS
PCAT-1 promotes development of OC and represses the chemoresistance of OC to cisplatin, and silencing of PCAT-1 may be a therapeutic strategy for treating OC.
FUNDING
None.
